Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.23)
# 2,785
Out of 5,147 analysts
40
Total ratings
50%
Success rate
-3.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $232 → $228 | $232.08 | -1.76% | 6 | Feb 5, 2026 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $15.62 | +130.47% | 1 | Dec 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $89 → $94 | $92.29 | +1.85% | 4 | Dec 9, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $40.79 | +137.80% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $26.00 | +53.85% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $30.22 | +115.09% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $766.92 | +18.66% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.38 | +914.49% | 4 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.59 | +214.47% | 1 | Apr 29, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $3.32 | +80.72% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $16.76 | +914.32% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.68 | +252.11% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $275.64 | -25.26% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.87 | +666.55% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.70 | +270.37% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $74.13 | -19.06% | 1 | Oct 5, 2022 |
AbbVie
Feb 5, 2026
Maintains: Outperform
Price Target: $232 → $228
Current: $232.08
Upside: -1.76%
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $15.62
Upside: +130.47%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $89 → $94
Current: $92.29
Upside: +1.85%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $40.79
Upside: +137.80%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $26.00
Upside: +53.85%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $30.22
Upside: +115.09%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $766.92
Upside: +18.66%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.38
Upside: +914.49%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.59
Upside: +214.47%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $3.32
Upside: +80.72%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $16.76
Upside: +914.32%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.68
Upside: +252.11%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $275.64
Upside: -25.26%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.87
Upside: +666.55%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.70
Upside: +270.37%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $74.13
Upside: -19.06%